A Phase III clinical study of a novel integrin beta antagonist (“Lifitegrast”), sponsored by Shire plc (LSE: SHP; NASDAQ: SHPG), has shown that twice-daily 5%… Read More »Phase III study of integrin antagonist for treatment of dry eye shows mixed results.
A Phase II clinical study of a novel integrin peptide therapy (ALG-1001), sponsored by Allegro Ophthalmics LLC, has commenced. According to the company, the study… Read More »Phase II study of integrin peptide therapy commences for vitreomacular traction.
Recent research from the Department of Health Statistics and Information Systems of the World Health Organisation (WHO), on behalf of the Vision Loss Expert Group,… Read More »Vision Loss Expert Group report almost a quarter of a billion people were either blind or visually impaired as of 2010.
Alimera Sciences, Inc. (NASDAQ: ALIM), Alpharetta, GA, have announced the receipt of a Complete Response Letter (CRL) from the FDA for their New Drug Application… Read More »Alimera announces receipt of Complete Response Letter for Iluvien from FDA
Clinical studies conducted at the Van Andel Research Institute in Michigan, USA have identified nineteen (19) cytokines significantly elevated in the vitreous of proliferative diabetic… Read More »Clinical analysis of proliferative diabetic retinopathy patients identifies new VEGF-independent cytokines
Roche (SIX: RO, ROG; OTCQX: RHHBY) have announced positive results from their Phase II study of lampalizumab (ant-factor D) for treatment of the advanced form… Read More »Roche report 18-month data on the use of lampalizumab for the treatment of dry AMD.
A UK-based stem cell company, ReNeuron, has announced receipt of both European and US orphan drug designation for an experimental therapy to treat retinitis pigmentosa.… Read More »Stem cell therapy receives European and US orphan drug designation for treatment of retinitis pigmentosa.
Researchers based at Kagoshima University’s Department of Ophthalmology in Japan have shown that OCT (optical coherence tomography) measures of reflectivity may be correlated with vascular… Read More »OCT reflectivity measurements may be able to predict VEGF levels to provide less invasive diagnostic and prognostic data for clinicians.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare have announced one-year results from two Phase 3 studies (VIVID-DME and VISTA-DME) evaluating “Eylea” (aflibercept) for the… Read More »Regeneron and Bayer announce 12-month results from Phase III studies of aflibercept injection for the treatment of DME
Researchers from University College London’s Institute of Ophthalmology and Moorfields Eye Hospital, in collaboration with Allergan, Inc., have published results evaluating the effect of a… Read More »Results from a clinical study with the DEX implant 0.7mg demonstrates significant improvement in visual function